Shanghai Pharmaceuticals Holding Co.,Ltd.(601607),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

601607 Shanghai Pharmaceuticals Holding Co.,Ltd.

Trading 12-24 09:30:13

17.92

-0.01

-0.06%

High17.92	Low17.91	Vol13.60K
Open17.91	D1 Closing17.93	Amplitude0.06%
Mkt Cap66.45B	Tradable Cap49.98B	Total Shares3.71B
T/O243.60K	T/O Rate0.00%	Tradable Shares2.79B
P/B0.88	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"Shanghai Pharmaceuticals Holding Co.,Ltd.","latestPrice":17.92,"timestamp":1766539813000,"preClose":17.93,"halted":0,"volume":13600,"delay":0,"changeRate":-0.0006,"floatShares":2789000000,"shares":3708000000,"eps":1.5224,"marketStatus":"Trading","change":-0.01,"latestTime":"12-24 09:30:13","open":17.91,"high":17.92,"low":17.91,"amount":243600,"amplitude":0.0006,"askPrice":17.92,"askSize":62,"bidPrice":17.91,"bidSize":389,"shortable":0,"etf":0,"ttmEps":1.5224,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1766547000000},"marketStatusCode":2,"adr":0,"adjPreClose":17.93,"symbolType":"stock","openAndCloseTimeList":[[1766539800000,1766547000000],[1766552400000,1766559600000]],"highLimit":19.72,"lowLimit":16.14,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.88,"roa":"--","peRate":11.770888,"roe":"6.96%","epsLYR":1.23,"committee":0.250883,"marketValue":66454000000,"turnoverRate":0,"status":1,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"SH PHARMA","latestPrice":11.76,"timestamp":1766538000005,"preClose":11.76,"halted":0,"volume":0,"delay":0,"premium":"-40.78"},"floatMarketCap":49983000000},"requestUrl":"/m/hq/s/601607/tweets","defaultTab":"tweets","newsList":[{"id":"1153257892","title":"Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines","url":"https://stock-news.laohu8.com/highlight/detail?id=1153257892","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153257892?lang=en_us&edition=fundamental","pubTime":"2025-12-15 16:12","pubTimestamp":1765786358,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0209","BK0183","BK0020","BK0097","BK0187","BK0028","BK1197","601607","02607","BK0184","BK0196","BK0099","BK0012","BK0188"],"gpt_icon":0},{"id":"1106253356","title":"SH PHARMA (02607) to Distribute Interim Dividend of HK$1.3215 per 10 Shares on February 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1106253356","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106253356?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:08","pubTimestamp":1765274891,"startTime":"0","endTime":"0","summary":"SH PHARMA (02607) announced that it will distribute an interim dividend of HK$1.3215 per 10 shares on February 6, 2026.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607","BK0183","BK0020","601607","BK0175","BK0188","BK0012","BK0196","BK0209","BK0184","BK0187","BK0099","BK1197","BK0028","BK0097"],"gpt_icon":0},{"id":"2590231284","title":"Shanghai Pharmaceuticals Holding Co. Ltd. held extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590231284","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590231284?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:00","pubTimestamp":1765274457,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co. Ltd. held an extraordinary general meeting on December 9, 2025. Proposals on the distribution and receipt of interim cash dividends and the abolishment of the Supervisory Board and related matters were considered. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLwQ48g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0209","BK0012","BK0020","BK0175","BK0099","BK0188","BK0184","BK0183","BK0196","601607","BK0028","BK0097"],"gpt_icon":0},{"id":"2589384001","title":"Shanghai Pharmaceuticals Terminates Cooperation Deal with Sinorg Biomedical","url":"https://stock-news.laohu8.com/highlight/detail?id=2589384001","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589384001?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:58","pubTimestamp":1765177131,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals (SHA:601607) terminated its cooperation agreement with Sinorg Biomedical regarding the novel acid suppressant X842, according to a Saturday filing with the Shanghai bourse.The","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0012","601607","BK0099","BK0188","BK0097","BK0028","BK0184","BK0196","BK0020","BK0183","BK0209","BK0187"],"gpt_icon":0},{"id":"1152073650","title":"Shanghai Pharmaceuticals (601607.SH) Gains Approval for Minoxidil Tincture Production","url":"https://stock-news.laohu8.com/highlight/detail?id=1152073650","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152073650?lang=en_us&edition=fundamental","pubTime":"2025-12-05 16:10","pubTimestamp":1764922231,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, SPD Jiangsu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate (No. 2025S03530, 2025S03531)...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0097","BK0028","BK0175","BK0099","BK0188","BK0020","02607","BK0184","BK0183","BK0209","BK0012","601607","BK0187","BK1197","BK0196"],"gpt_icon":0},{"id":"1163538559","title":"SH PHARMA (02607) to Distribute Interim Dividend of RMB1.2 per 10 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1163538559","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163538559?lang=en_us&edition=fundamental","pubTime":"2025-11-18 16:54","pubTimestamp":1763456057,"startTime":"0","endTime":"0","summary":"SH PHARMA (02607) announced that it will distribute an interim dividend of RMB1.2 per 10 shares for the six months ended June 30, 2025.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0184","BK0209","BK0020","601607","BK0188","02607","BK0028","BK0183","BK0099","BK0196","BK0187","BK0097","BK0175","BK1197","BK0012"],"gpt_icon":0},{"id":"2584875649","title":"Shanghai Pharmaceuticals Holding Co. Ltd. proposes interim dividend of RMB 1.2 per 10 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584875649","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584875649?lang=en_us&edition=fundamental","pubTime":"2025-11-18 16:52","pubTimestamp":1763455932,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co. Ltd. has announced an interim ordinary dividend of RMB 1.2 per 10 shares for the six months ended 30 June 2025. This value represents the declared dividend and follows the approval by shareholders scheduled for 9 December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLfhNlN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0184","BK0028","BK0196","BK0209","BK0175","601607","BK0187","BK0020","BK0183","BK0188","BK0099","BK0097","BK0012"],"gpt_icon":0},{"id":"1133091160","title":"Shanghai Pharmaceuticals (601607.SH): Cefuroxime Sodium for Injection and Aztreonam for Injection Pass Generic Drug Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1133091160","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133091160?lang=en_us&edition=fundamental","pubTime":"2025-11-10 15:42","pubTimestamp":1762760540,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd. (\"Shangyao Xinya\"), recently received the \"Drug Supplement...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0184","BK0028","BK0196","BK0209","BK0175","02607","601607","BK0187","BK0020","BK0183","BK0188","BK1197","BK0099","BK0097","BK0012"],"gpt_icon":0},{"id":"1144037518","title":"Shanghai Pharmaceuticals (601607.SH) Receives FDA Approval for Ticagrelor Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1144037518","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144037518?lang=en_us&edition=fundamental","pubTime":"2025-11-06 17:18","pubTimestamp":1762420707,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently received notification from the U.S. Food and Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","02607","BK0188","601607","BK0099","BK0028","BK0187","BK0209","BK0020","BK0183","BK0184","BK0196","BK0012","BK0097","BK1197"],"gpt_icon":0},{"id":"1192970202","title":"Shanghai Pharmaceuticals (601607.SH): Tofacitinib Citrate Sustained-Release Tablets Approved for Production","url":"https://stock-news.laohu8.com/highlight/detail?id=1192970202","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192970202?lang=en_us&edition=fundamental","pubTime":"2025-11-06 17:18","pubTimestamp":1762420698,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the Drug Registration...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0175","BK0196","BK0012","BK0188","BK0184","BK0028","BK0020","BK0183","02607","BK0209","BK0099","601607","BK0097","BK1197"],"gpt_icon":0},{"id":"1138336809","title":"UBS Raises SH PHARMA (02607) Target Price to HK$15, Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1138336809","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138336809?lang=en_us&edition=fundamental","pubTime":"2025-11-03 16:42","pubTimestamp":1762159345,"startTime":"0","endTime":"0","summary":"UBS issued a research report adjusting its forecasts for SH PHARMA (02607). The bank raised its 2025 EPS estimate by 7% to reflect one-time gains from the SHPL merger but lowered 2026/27 EPS...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0099","BK0188","BK0020","BK0196","BK0028","BK0209","601607","BK0187","BK0012","02607","BK0175","BK1197","BK0097","BK0184"],"gpt_icon":0},{"id":"1194972729","title":"HK Stock Movement | SH PHARMA (02607) Drops Over 5% as Q3 Net Profit Falls 38.13% Due to Increased Asset Impairment Provisions","url":"https://stock-news.laohu8.com/highlight/detail?id=1194972729","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194972729?lang=en_us&edition=fundamental","pubTime":"2025-10-31 11:34","pubTimestamp":1761881651,"startTime":"0","endTime":"0","summary":"SH PHARMA (02607) fell more than 5%, dropping 5.11% to HK$11.71 by the time of writing, with a trading volume of HK$109 million. The decline follows the company's release of its Q3 2025 financial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","02607","BK0097","BK0020","BK0175","BK0209","BK0184","BK1197","BK0183","BK0099","BK0196","601607","BK0012","BK0187","BK0028"],"gpt_icon":0},{"id":"1186805828","title":"Shanghai Pharmaceuticals Plans to Distribute 1.2 Yuan Cash Dividend per 10 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1186805828","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186805828?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:31","pubTimestamp":1761827491,"startTime":"0","endTime":"0","summary":"On October 30, Shanghai Pharmaceuticals Holding Co., Ltd. (601607/02607) announced its plan to distribute a cash dividend of 1.2 yuan per 10 shares (tax inclusive) to all shareholders. The total...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","601607","BK0020","BK0184","BK0183","BK0188","BK0028","BK0097","BK0099","BK0175","BK0012","BK0187","BK0196","02607","BK0209"],"gpt_icon":0},{"id":"2579762116","title":"Shanghai Pharmaceuticals Holding Co. Ltd. proposes RMB445 million interim dividend for H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579762116","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579762116?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:10","pubTimestamp":1761819056,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co. Ltd. has proposed an interim cash dividend of RMB1.20 for every ten shares for the first half of 2025, based on a total share capital of 3,708,361,809 shares as of June 30, 2025. The proposal is pending approval at a future shareholder meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL9n5hn7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0184","BK0209","BK0020","601607","BK0188","BK0028","BK0183","BK0099","BK0196","BK0187","BK0097","BK0175","BK0012"],"gpt_icon":0},{"id":"2579319024","title":"BRIEF-Shanghai Pharmaceuticals Q3 Net Profit Down 38.1% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2579319024","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579319024?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:22","pubTimestamp":1761816174,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Pharmaceuticals Q3 Net Profit Down 38.1% Y/YOct 30 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd 601607.SS:Q3 NET PROFIT DOWN 38.1% Y/YSource textFurther company coverage: 601607.SS (Reporting by Beijing Newsroom) ((yukun.zhang@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL4N3WB15L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0209","BK0175","BK0020","BK0099","BK0188","BK0187","BK0184","BK0196","601607","BK0097","BK0183","BK0012","BK0028"],"gpt_icon":0},{"id":"2579197705","title":"SIHL Subsidiary Signs One-Year Procurement Framework Agreement with Shanghai Pharmaceuticals Holding","url":"https://stock-news.laohu8.com/highlight/detail?id=2579197705","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579197705?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:11","pubTimestamp":1761815468,"startTime":"0","endTime":"0","summary":"Shanghai Industrial Holdings Limited  announced that on 30 October 2025, its indirect non-wholly owned subsidiary, Wing Fat Printing, entered into a Procurement Framework Agreement with Shanghai Pharmaceuticals Holding. The agreement is set for a term of one year commencing from 1 January 2026. The transactions under this agreement are classified as continuing connected transactions under the Hong Kong Listing Rules and are subject to reporting, announcement, and annual review requirements, but are exempt from independent shareholders' approval. None of the Directors had a material interest in the agreement, though certain directors voluntarily abstained from voting on the relevant Board resolutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL5wKjlN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0099","BK0183","00363","BK0020","BK0012","BK0175","BK0187","BK1230","BK0097","BK0209","601607","BK0028","BK0184","BK0196"],"gpt_icon":0},{"id":"1187578498","title":"Shanghai Pharmaceuticals (601607.SH): Pyridostigmine Bromide Sustained-Release Tablets Approved for Production","url":"https://stock-news.laohu8.com/highlight/detail?id=1187578498","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187578498?lang=en_us&edition=fundamental","pubTime":"2025-10-28 15:40","pubTimestamp":1761637218,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the \"Drug Registration...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK0183","02607","BK0187","BK0175","BK0028","BK0188","BK0099","BK0184","BK0020","BK0209","BK0012","601607","BK0097","BK0196"],"gpt_icon":0},{"id":"1127558805","title":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1127558805","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127558805?lang=en_us&edition=fundamental","pubTime":"2025-10-24 15:42","pubTimestamp":1761291737,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0099","601607","BK0020","02607","BK0097","BK0187","BK0196","BK0175","BK0183","BK1197","BK0012","BK0028","BK0188","BK0184","BK0209"],"gpt_icon":0},{"id":"2575299075","title":"Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2575299075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575299075?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:51","pubTimestamp":1760439060,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding Co. Ltd. has announced the completion of an equity adjustment involving its controlling shareholder. The reorganization included the transfer of Shanghai Shangshi  Co., Ltd.'s 100% equity interest in Shanghai Tandong Enterprise Consulting Services Co., Ltd. to SIIC International Investment Company Limited, as well as the disposal of a 40% equity interest in Shanghai Pharmaceutical  Co., Ltd. With these transactions, SIIC International increased its shareholding to 301,418,000 H shares, and Shanghai Shangshi's indirect control of the company rose from 25.303% to 38.487%. The company stated that the equity adjustment will not result in any change to its controlling shareholder or de facto controller.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLbzQsQv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0099","601607","BK0020","BK0028","BK0187","BK0196","BK0175","BK0183","BK0012","BK0097","BK0188","BK0184","BK0209"],"gpt_icon":0},{"id":"2575299036","title":"Shanghai Pharmaceuticals -  Shanghai Shangshi Increased Shareholding in Co From 25.303% to 38.487% Following Equity Adjustment","url":"https://stock-news.laohu8.com/highlight/detail?id=2575299036","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575299036?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:49","pubTimestamp":1760438976,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VU2ZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0099","BK0028","BK0012","BK0097","BK0196","BK0209","BK0184","601607","BK0188","BK0183","BK0187","BK0175","BK0020"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","stockEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":0.0119},{"period":"3month","weight":-0.0061},{"period":"6month","weight":0.0274},{"period":"1year","weight":-0.1564},{"period":"ytd","weight":-0.1331}],"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","perCapita":"--","boardName":"零售业","registeredCapital":"370836万元","compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1367},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.1695}],"survey":"　　上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。","serverTime":1766539812005,"listedPrice":4.5,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Pharmaceuticals Holding Co.,Ltd.(601607),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Pharmaceuticals Holding Co.,Ltd.(601607) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Pharmaceuticals Holding Co.,Ltd.,601607,Shanghai Pharmaceuticals Holding Co.,Ltd.股票,Shanghai Pharmaceuticals Holding Co.,Ltd.股票老虎,Shanghai Pharmaceuticals Holding Co.,Ltd.股票老虎国际,Shanghai Pharmaceuticals Holding Co.,Ltd.行情,Shanghai Pharmaceuticals Holding Co.,Ltd.股票行情,Shanghai Pharmaceuticals Holding Co.,Ltd.股价,Shanghai Pharmaceuticals Holding Co.,Ltd.股市,Shanghai Pharmaceuticals Holding Co.,Ltd.股票价格,Shanghai Pharmaceuticals Holding Co.,Ltd.股票交易,Shanghai Pharmaceuticals Holding Co.,Ltd.股票购买,Shanghai Pharmaceuticals Holding Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Pharmaceuticals Holding Co.,Ltd.(601607),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Pharmaceuticals Holding Co.,Ltd.(601607) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction